Study: Seniors on 5+ Prescription Drugs Face 38% Higher Death Risk

More pills, more risk. That's the finding from a study published in the Journal of the American Geriatrics Society, led by Dr. Alexander Chaitoff of the University of Michigan School of Medicine.

Researchers pulled national survey data on 7,828 adults age 65 and older, collected between 1999 and 2016. This wasn't a self-report survey where people guess what they're taking. Trained staff physically inspected participants' pill bottles to verify what they'd actually used over the prior 30 days, according to a press release on the study. Then they tracked those people for an average of 8.5 years.

The number is stark. Taking five or more prescription drugs, the clinical definition of polypharmacy, was associated with a 38% jump in overall mortality risk after researchers accounted for participants' underlying health conditions. Every additional drug piled on top added another 7% to that risk.

Most Seniors Are Already In The Danger Zone

This isn't a fringe problem affecting a small slice of elderly patients. More than half the study group, 54.3%, fell into at least one high-risk medication category. The single largest chunk of that group was people taking five or more prescriptions.

Separately, 37.6% of participants were on medications considered risky specifically for older adults, drugs that raise the odds of confusion or falls. And 11.4% were taking drug combinations known to cause serious interactions.

The sheer total number of medications a person was taking turned out to be the strongest predictor of death, stronger than whether those drugs interacted badly with each other or whether any single one was inappropriate for an older patient. Volume mattered more than any specific bad combination.

Why This Happens

Aging bodies process drugs differently. According to medical experts at Cleveland Clinic, the liver and kidneys slow down with age, meaning medications linger longer and build up in ways they wouldn't in a younger patient. Stack five, ten, or more prescriptions on top of that slower metabolism and the odds of side effects, adverse reactions, and accidental overdose climb.

Polypharmacy often isn't the result of one doctor making a bad call. It's usually the byproduct of a fragmented healthcare system: a cardiologist prescribes a blood pressure drug, a separate specialist adds something for arthritis, a primary care doctor throws in a sleep aid, and nobody sits down to ask whether the whole stack still makes sense together. Each addition might be individually reasonable. The accumulation is where the risk lives.

What Comes Next: Deprescribing

The researchers say their findings should help doctors identify which patients are good candidates for "deprescribing," the deliberate, careful process of reducing or stopping medications that are no longer necessary or that carry more risk than benefit.

Medicine has spent decades optimized around adding treatment for every new symptom or diagnosis. This study supports a different approach: periodically auditing an older patient's entire drug list and asking what can be safely removed, not just what should be added.

None of this means every senior on multiple medications is in danger, and nobody should stop taking a prescribed drug based on a news article. The study establishes an association between drug count and mortality risk, not proof that any specific medication caused any specific death. Confounding factors are always a risk in observational research like this, even after statistical adjustment for underlying health.

An 8.5-year follow-up period and a sample size approaching 7,800 people gives this finding real weight. The unresolved question is practical: how many primary care doctors currently have the time, incentive, or coordinated patient records to actually run a deprescribing review, especially for patients juggling multiple specialists who rarely talk to each other. That's a systems problem, and this study doesn't solve it. It just makes clear how much is riding on somebody solving it.